Navigation Links
ConvaTec Announces 2014 Second Quarter Earnings Call
Date:8/14/2014

LUXEMBOURG, Aug. 14, 2014 /PRNewswire/ -- ConvaTec today announced that it will hold an analyst and investor call to discuss 2014 second quarter results on Tuesday, August 19, 2014. Ken Berger, CEO, and Nigel Clerkin, CFO, will host the call at 9:00 AM ET live via telephone.

To participate in the conference call within the U.S. and Canada, dial (877) 366-0267.

To participate in the conference call outside the U.S. and Canada, dial (760) 666-3086.

The conference ID is 88736401.

Participants should dial in 10 minutes prior to the start of the call. The Company's 2014 Second Quarter Report will be available on the Company's website prior to the call under the Investors tab at www.convateccorporate.com.

For more information, please contact investorrelations@convatec.com.

About ConvaTec
ConvaTec is a global medical products and technologies company, with leading market positions in wound therapeutics, ostomy care, continence and critical care, and infusion devices. Our products provide a range of clinical and economic benefits, including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. ConvaTec has over 8,000 employees, with 11 manufacturing sites in 8 countries, and we do business in more than 100 countries. We are owned by Nordic Capital and Avista Capital Partners. More information is available at www.convatec.com.

Contacts

Investor Relations:
Robert McKee
Senior Vice President
ConvaTec
336-547-3701
investorrelations@convatec.com

Media Relations:
Punnie Donohue
Director
ConvaTec
336-297-3087
mediarelations@convatec.com


'/>"/>
SOURCE ConvaTec
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Elsevier Announces 2013 Journal Impact Factor Highlights
2. Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients Highly Warranted
3. NORD Announces Agenda for 2014 Rare Diseases and Orphan Products Breakthrough Summit
4. Whitehouse Laboratories Announces Participation at 13th Annual Contract Pharma Conference
5. FutureCeuticals Announces Publication of Human Clinical Study on ability of a dietary supplement ingredient to inhibit free radical production in vivo
6. BioNano Genomics Announces The Purchase Of The Irys System By The Wellcome Trust Sanger Institute
7. FlexTech Alliance Announces 2015FLEX Conference Theme, Call for Papers and Advisory Committee
8. Fertility Associates of Memphis Announces New Physician
9. Regado Biosciences Announces Second Quarter 2014 Financial Results and Corporate Highlights
10. OXIS International announces plans to Enter the Cannabis Biotech Sector, Completion of Financing, Changes to the Board of Directors
11. Braskem announces 2Q14 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... platform specifically designed for life science researchers to analyze and interpret datasets, ... Franklin, who made a major contribution to the discovery of the double-helix ...
(Date:10/11/2017)... Palo Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... is set to take place on 7th and 8th June 2018 in San Francisco, ... and policy influencers as well as several distinguished CEOs, board directors and government officials ...
(Date:10/11/2017)... ... 2017 , ... Disappearing forests and increased emissions are the main causes of ... year. Especially those living in larger cities are affected by air pollution related diseases. ... most pollution-affected countries globally - decided to take action. , “I knew I had ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
Breaking Biology Technology:
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):